Biomimetic Therapeutics Inc

Biomimetic Therapeutics — Technical Presentation (July 2007)

24 slides from Biomimetic Therapeutics's technical presentation, Jul 16, 2007

  1. Slide 1: Pilot Clinical Trials to Assess rhPDGF in Foot/Ankle Arthrodesis

    Pilot Clinical Trials to Assess rhPDGF in Foot/Ankle Arthrodesis United States: Chris DiGiovanni, MD, Brown U Judy Baumhauer, MD, Rochester U Sheldon S. Lin*, MD, UMDNJ Co-I: Adolph Flemister, MD, Wayne Berberian, MD Peter Evangelista, MD Canada: Tim Daniels, MD, St. Michael's Hospital Johnny T.C. L

  2. Slide 2: Hindfoot Procedures in United States

    Hindfoot Procedures in United States Foot Ankle : Knowledge Enterprises, 2005 Ankle Triple Sub TAA 2001 9059 6005 8771 0 2002 11259 6189 10851 1439 2003 11953 6499 12780 1327

  3. Slide 3: Iliac crest: Gold Standard Use of Autologous Bone Grafting does come with a Price

    Iliac crest: Gold Standard Use of Autologous Bone Grafting does come with a Price 340,000 patients undergo iliac crest harvest annually Significant Morbidity Complications rate as high as 31%

  4. Slide 4: BMPs and PDGF: Bone Regeneration

    PDGF Chemotaxis Proliferation Hollinger. PDGFs and BMPs in periodontics and orthopedics. 2007 Osteoblasts Progenitor cells Angiogenesis PDGF Chemotaxis Proliferation PDGF, TGF-b BMPs and PDGF: Bone Regeneration Chondrocytes BMPs Platelets Progenitor cells Factors released from bone matrix .. .. .. .

  5. Slide 5: Role of PDGF in Bone Remodeling

    Osteoclasts Resorb 20-40 µm/day 1-2 µm/day 20 µm thick, maturation of 10-20 days, mineralizes 1-2 µm/day Osteoblast ~ 2 wk lifespan ~ 1-3 mos lifespan Activation Resorption Formation Osteoid Role of PDGF in Bone Remodeling Cutting cones PDGF: REMODELING Osteoblastogenesis Osteoclastogenesis Angiogen

  6. Slide 6: rhPDGF: Role in Tissue Healing

    rhPDGF: Role in Tissue Healing 2005 Maxillofacial > 1 yr (BioMimetic Therapeutics) 1999 chronic DM foot ulcers > 7 yrs (Johnson & Johnson)

  7. Slide 7: rhPDGF Enhances Osteoporotic Bone Formation in Rat OVX Model

    Mitlak et al, 1996 Control Control 14% 25%* 27% 46%* PDGF PDGF *p<0.05 Decreased bone density PDGF Restored bone density rhPDGF Enhances Osteoporotic Bone Formation in Rat OVX Model TRABECULAR BONE DENSITY (%) Vertebra (L5): % INCREASE Tibial metaphysis: % INCREASE

  8. Slide 8: rhPDGF Enhances Diabetic Rat Femur Fracture Healing

    rhPDGF Enhances Diabetic Rat Femur Fracture Healing

  9. Slide 9: rhPDGF Increased Bone Formation in Diabetic Rats

    Minimal trabecular bone Robust trabecular bone Non treated PDGF-Treated cortical bone Increase in cortical bone rhPDGF Increased Bone Formation in Diabetic Rats S Lin, MD

  10. Slide 10: Two Foot/Ankle Fusion Clinical Trials

    United States Canada Number of Centers 3 3 Number of Subjects 20 20 60 Type of Study Randomized, Controlled Open-Label (GEM OS1 only) Control Autograft None Follow-Up 3 mo. CT 9 mo. safety 3 mo. CT 9 mo. safety Primary Endpoint Radiographic Healing/Union Radiographic Healing/Union Secondary Endpoint

  11. Slide 11: GEM OS1

    GEM OS1 rhPDGF-BB ^ -TCP

  12. Slide 12: Patient Demographics

    US Autograft N=6 US GEM OS1 N=14 CAN GEM OS1 N=60 Patient Age 43.7 55.2 53.4 Body Mass Index (BMI) 30.5 29.8 29.0 % Smoker/ Smoking history 17% (1 of 6) 50% (7 of 14) 60% (36 of 60) Revision of previous surgery - - 33% (20 of 60) Injury/Deformity 70% Post-traumatic injury 15% Primary Arthritis 10% R

  13. Slide 13: Safety and AOFAS Scores

    US US Canada Timepoint ABG (n=6) GEM OS1 (n=14) GEM OS1 (n=60) Baseline 36.3 39.2 48.1 Week 6 52.3 56.2 49.0 Week 12 58.2 59.2 63.0 Safety and AOFAS Scores No device related AEs / SAEs reported to date

  14. Slide 14: Donor Site Pain and Procedure Time

    US Autograft US GEM OS1 CAN GEM OS1 Donor Site Pain Week 12 12.4 - - Procedure Time (minutes) 144 118 105 Donor Site Pain and Procedure Time

  15. Slide 15: Ankle Fusion using GEM OS1

    Ankle Fusion using GEM OS1 Case courtesy of C.D.

  16. Slide 16: Immediate Post-op

    Immediate Post-op

  17. Slide 17: CT Scan at weeks

    CT Scan at 12 weeks XXXXXXXXXXX

  18. Slide 18: Comparison of Data to Published ABG Data Using CT Scans

    United States United States Canada Published CT mean observed fusion for ABG in hindfoot* ABG (N=6) GEM OS1 (N=13) GEM OS1 (N=56) ABG (N=15) Week 6 33% 39% 42% 23% Week 12 50% 69% 70% 48% Week 24 64% Comparison of Data to Published ABG Data Using CT Scans *Coughlin et al, FAI, 2006

  19. Slide 19: Results of Pilot Clinical Trials

    Results of Pilot Clinical Trials Comparable to published data using ABG US: two delayed unions Case#PS Mitigating factor: S/P talus fracture undiagnosed Diabetes M; smoker REVISION SURGERY with autograft STILL did not heal Case # JB Possible factors: Co-Morbidities & over packing the joint

  20. Slide 20: Delayed Union / Nonunion

    Delayed Union / Nonunion "In this study, the nonunion rate was 41%" Majority of the patients were post-traumatic. Highest incidence in patients with plafond/talus fractures A review of ankle arthrodesis: predisposing factors to nonunion. Frey C et al Foot Ankle Int. 1994 Nov;15(11):581-4.

  21. Slide 21: Delayed Union / Nonunion: Isolated Subtalar Arthrodesis

    Delayed Union / Nonunion 184 consecutive isolated subtalar arthrodesis Overall nonunion rate = 16% Nonunion rate: Nonsmokers - 8% Smokers - 27% Nonunion rate in: Primary fusion - 14% Revision fusion - 29% Isolated Subtalar Arthrodesis Easley ME, Trinka HJ, Schon LC and Myerson MS J Bone Joint Surg A

  22. Slide 22: Are there advantages of GEM OS1 over autograft?

    Are there advantages of GEM OS1 over autograft? AVOID PAIN at the donor site SHORTER OR Time LESS Morbidity 31% complication rate with ICBG rate with ICBG

  23. Slide 23: Summary and Conclusions

    To date GEM OS1 appears to be a safe alternative to autogenous bone graft No device related SAEs Results comparable to ABG without harvest morbidity Rigid fixation and bony apposition are critical for efficacy ~396 patient, 28 center randomized controlled pivotal clinical trial underway Rigorous met

  24. Slide 24: Thank you

    Thank you

BioMimetic Therapeutics — Technical Presentation (July 2007) on 6ix